ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Pepperstone

Trade Now

Pepperstone
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P ASX 200
8,203.70
0.95%
S&P ASX All Technology
3,433.00
1.97%
Brent Oil
71.095
-2.86%
US Dollar vs AUD
1.45081
-1.03%
Bitcoin
65,179.01
3.24%
Registration Strip Icon for smarter Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NYSE
  6. Johnson and Johnson (JNJ)

  7. Johnson and Johnson (JNJ) News

JNJ

Johnson and Johnson (JNJ)

Johnson and Johnson
Date:
Sort by:
 Showing the most relevant articles for your search:NYSE:JNJ
DateTimeSourceHeadlineSymbolCompany
23/09/202420:32IH Market NewsApollo Eyes $5 Billion Investment in Intel; TSMC and Samsung Explore UAE Chip Projects, and MoreNYSE:JNJJohnson and Johnson
21/09/202408:53Business WireAttorneys Vow to Oppose J&J’s Third Bankruptcy AttemptNYSE:JNJJohnson and Johnson
21/09/202406:19Edgar (US Regulatory)Form 8-K - Current reportNYSE:JNJJohnson and Johnson
21/09/202405:43Business WireJohnson & Johnson Announces that its Subsidiary, Red River Talc LLC, has Filed a Voluntary Prepackaged Chapter 11 Case to Resolve All Current and Future Ovarian Cancer Talc ClaimsNYSE:JNJJohnson and Johnson
20/09/202408:54PR Newswire (US)RYBREVANT® (amivantamab-vmjw) plus standard of care approved in the U.S. as first and only targeted regimen to cut risk of disease progression by more than half in second-line EGFR-mutated advanced lung cancerNYSE:JNJJohnson and Johnson
17/09/202420:40IH Market NewsMicrosoft Boosts Share Buyback, Raises Dividends by 10%, Intel Secures Chip Deal with AmazonNYSE:JNJJohnson and Johnson
16/09/202416:50PR Newswire (US)Neoadjuvant TAR-200 plus cetrelimab nearly doubles the pathological complete response rate compared to cetrelimab alone in patients with muscle-invasive bladder cancerNYSE:JNJJohnson and Johnson
15/09/202416:30PR Newswire (US)New data from TAR-200 Phase 2b SunRISe-1 study show 84 percent complete response rate in patients with high-risk non-muscle-invasive bladder cancerNYSE:JNJJohnson and Johnson
14/09/202423:45PR Newswire (US)RYBREVANT® (amivantamab-vmjw) plus chemotherapy show 49 percent overall response rate in metastatic colorectal cancerNYSE:JNJJohnson and Johnson
14/09/202417:10PR Newswire (US)RYBREVANT® (amivantamab-vmjw) plus chemotherapy shows positive overall survival trend versus chemotherapy in patients with previously treated EGFR-mutated lung cancerNYSE:JNJJohnson and Johnson
13/09/202406:44Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:JNJJohnson and Johnson
13/09/202406:43Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:JNJJohnson and Johnson
12/09/202408:22PR Newswire (US)TREMFYA® (guselkumab) receives U.S. FDA approval for adults with moderately to severely active ulcerative colitis, strengthening Johnson & Johnson's leadership in inflammatory bowel diseaseNYSE:JNJJohnson and Johnson
11/09/202407:15PR Newswire (US)Dexamethasone reduces infusion-related reactions in patients with EGFR-mutated non-small cell lung cancer treated with intravenous RYBREVANT® (amivantamab-vmjw)NYSE:JNJJohnson and Johnson
11/09/202406:26Edgar (US Regulatory)Form 8-K - Current reportNYSE:JNJJohnson and Johnson
09/09/202403:47PR Newswire (US)RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE™ (lazertinib) show strong favorable overall survival trend versus osimertinib in EGFR-mutated advanced lung cancerNYSE:JNJJohnson and Johnson
06/09/202406:30Business WireJohnson & Johnson to Host Investor Conference Call on Third-Quarter ResultsNYSE:JNJJohnson and Johnson
05/09/202420:11IH Market NewsQualcomm Develops Mixed Reality Glasses; Verizon to Boost Dividend, Eyes Acquisition; Samsonite Plans US Dual ListingNYSE:JNJJohnson and Johnson
04/09/202406:48Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:JNJJohnson and Johnson
31/08/202405:51Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNYSE:JNJJohnson and Johnson
30/08/202404:05Edgar (US Regulatory)Form N-PX - Annual Report of proxy voting record of management investment companiesNYSE:JNJJohnson and Johnson
29/08/202422:00PR Newswire (US)Johnson & Johnson seeks first approval of nipocalimab to treat broadest population living with antibody positive generalized myasthenia gravisNYSE:JNJJohnson and Johnson
27/08/202422:00PR Newswire (US)Johnson & Johnson is transforming solid tumor cancer outcomes with new data at the 2024 World Conference on Lung Cancer and European Society for Medical Oncology CongressNYSE:JNJJohnson and Johnson
27/08/202406:26Edgar (US Regulatory)Form 8-K - Current reportNYSE:JNJJohnson and Johnson
26/08/202422:58IH Market NewsIBM Closes China Research Division, Uber Fined $324M, Starliner to Return Without AstronautsNYSE:JNJJohnson and Johnson
26/08/202422:00Business WireJohnson & Johnson’s Executive Vice President, Chief Human Resources Officer Peter Fasolo to Retire; Kristen Mulholland Named Chief Human Resources Officer, Effective October 1, 2024NYSE:JNJJohnson and Johnson
21/08/202422:12IH Market NewsWalmart Sells JD.com Stake, Microchip Suffers Cyberattack, Union Pacific Warns of Strike in Canada, and Latest NewsNYSE:JNJJohnson and Johnson
20/08/202421:30Business WireJohnson & Johnson to Acquire V-WaveNYSE:JNJJohnson and Johnson
20/08/202421:00PR Newswire (US)RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE™ (lazertinib) approved in the U.S. as a first-line chemotherapy-free treatment for patients with EGFR-mutated advanced lung cancerNYSE:JNJJohnson and Johnson
15/08/202420:05IH Market NewsGoogle Mandated to Modify Play Store, Apple Innovates, Victoria’s Secret Hires CEO, Mars Buys KellanovaNYSE:JNJJohnson and Johnson
 Showing the most relevant articles for your search:NYSE:JNJ

Your Recent History

TG
0M4
Mersana Therapeutics
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Australia
Company
Business
Popular
Get The App
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved